Product name:BACLOFEN 20 MG Tablet
Company name:
DIN:02224087
Status:Marketed
Status date:2020-03-01
| Active ingredient(s) | Strength |
|---|---|
| BACLOFEN | 20 MG |
Click on a resource to visit a page with more information. You may be taken away from this page to a different Government of Canada website.
For consumers| Resource | Description |
|---|---|
The Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use. The Product Monograph includes three sections:
| |
Side effects are troublesome symptoms or feelings that you may not expect that show up when you are taking a medicine. All suspected side effects should be reported, especially those that are:
|
Section C.01.020.1 of the Food and Drug Regulations and section 62 of the Medical Devices Regulations, require hospitals to report to Health Canada all serious adverse drug reactions (ADRs) and medical device incidents (MDIs) within 30 days of being documented within the hospital. This regulatory requirement only applies to hospitals. |
| After Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes. |
When it comes to treating spasticity, baclofen can be one of the most important medications available for a range of neurological conditions. It is often used as a first line treatment in spinal cord injuries, particularly for spinal cord injuries or in patients who may have difficulty in getting and/or maintaining their muscles with flexors or dystrophins. It is important to consider how baclofen works in different conditions to make sure that the best treatment for your specific condition is tailored to the patient's needs.
Baclofen, a derivative of gamma-aminobutyric acid (GABA), has shown effectiveness in the treatment of spasticity. It is classified as a selective gamma-aminobutyric acid (GABA) receptor agonist. Baclofen has the ability to inhibit GABA-A, GABA-B receptors, leading to relaxation of muscles and alleviating dystrophic muscles.
Baclofen is a GABA receptor agonist, which means it blocks the negative feedback of gamma-aminobutyric acid receptors (GABA receptors) at the postsynaptic cleft. The result is a positive effect on GABA-A, reducing the negative feedback of GABA-B receptors.
Baclofen blocks the negative feedback of GABA-A receptors, leading to relaxation of muscles and alleviation of dystrophic muscles.
Like any medication, baclofen may cause side effects. In some cases, these side effects are more pronounced than others. These side effects usually go away after a few days or weeks. It is important to monitor any side effects while taking baclofen, especially in the first couple of days. If you experience severe side effects, such as weakness or difficulty with movement, stop taking baclofen and seek medical attention immediately. In rare cases, more severe side effects may occur, such as muscle rigidity or spasms.
If you experience any serious side effects while taking baclofen, stop taking the medication and seek medical attention immediately. These side effects usually go away within a few days or weeks of starting treatment.
Baclofen is not suitable for everyone. In certain cases, it may be harmful for people with certain conditions. It is important to follow the advice of a doctor, as baclofen may not be suitable for everyone. It is also important to avoid using other medications, such as benzodiazepines or anticonvulsants, as they may interact with baclofen.
It is also important to discuss any medications you are taking with your doctor before starting treatment with baclofen. This may include some supplements, over-the-counter medications, and herbal remedies.
In general, baclofen is generally well-tolerated, but it is not a cure-all. It is also not suitable for everyone, especially those with specific needs or those with existing health conditions.
It is important to discuss the use of baclofen with your doctor before starting treatment with it. It may not be suitable for everyone, especially if you are pregnant or breastfeeding.
There is no specific dosing regimen for baclofen, but it is usually recommended that you take the lowest effective dose for the shortest possible time. It is important to discuss the dose and duration of treatment with your doctor. This can help ensure that you are getting the maximum benefit from the medication.
This article was originally published in the March 2022 issue. This article is part of a special issue series.
What causes spasticity in dogs?
Spasticity is an involuntary, involuntary, and progressive muscle spasm. It occurs because the muscle tightens up (become stiff) to produce stiff muscle. It is not uncommon, however, when the spasm is not due to any other cause.
A dog can have spasticity due to various conditions, including injury, infection, illness, injury, surgery, surgery of the lower abdomen, spinal cord, and other spinal cord injuries. In some cases, dogs have other conditions that may lead to spasticity such as cerebral palsy.
In the following, the causes of spasticity in dogs are discussed. These causes are often conditions of the central nervous system, such as spasm and muscle spasm.
The most common conditions that cause spasticity are the following:
A condition that can cause spasticity in dogs is called spasticity and is characterized by a muscle stiffness. This condition causes the muscles to tighten up when they are stressed. Spasms are typically reversible.
In order to understand the causes of spasticity in dogs, it is important to know a bit more about the various conditions that cause it.
What are the most common conditions that cause spasticity in dogs?
The most common conditions that cause spasticity in dogs are:
There are many different conditions that cause spasticity in dogs. These conditions are usually due to a combination of the following:
What are the treatments for spasticity in dogs?
There are a few different types of medications that can be used to treat spasticity in dogs. These medications may be used as part of a treatment plan to reduce the symptoms of the spasticity. Some medications that may be used to treat spasticity in dogs are:
The medications that may be used to treat spasticity in dogs are:
Baclofen is a muscle relaxant and has been used to treat muscle spasms, muscle pain, and muscle stiffness. Baclofen is also sometimes used to treat muscle spasticity. It works by decreasing muscle tone and decreasing muscle rigidity, which can help improve muscle function and exercise performance. Baclofen is used to treat spasticity, muscle spasms, and muscle stiffness, but it also has other muscle-relaxant properties. These include:
• Muscle relaxant effects include:
• Increased muscle tone in muscle cells
• Increased stiffness and spasms
• Increased blood pressure
• Increased muscle tone and stiffness
• Increased muscle spasms and muscle stiffness
Baclofen is available in various dosage forms. It is important to use baclofen correctly and use it exactly as prescribed, and to take it exactly as prescribed.
Baclofen is a muscle relaxant that works by decreasing muscle tone and muscle rigidity. It is also used to treat muscle spasticity. Baclofen is also used to treat muscle stiffness, which can be caused by:
Baclofen is also sometimes used to treat muscle spasticity, muscle pain, and muscle stiffness. It works by decreasing muscle tone and muscle rigidity. It is also used to treat muscle spasticity, muscle pain, and muscle stiffness. This may include:
Baclofen is also sometimes used to treat muscle spasticity, muscle pain, and muscle stiffness, but it also has other muscle-relaxant properties.
Baclofen is sometimes used to treat muscle spasticity, muscle pain, and muscle stiffness, but it also has other muscle-relaxant properties.
The use of intrathecal baclofen for the management of spasticity and the reduction of muscle spasms has gained significant attention. In this review, we will delve into the mechanisms of intrathecal baclofen, including the role of baclofen, the efficacy of intrathecal baclofen therapy and the importance of monitoring patient response to treatment.
Baclofen is a muscle relaxant that selectively and reversibly inhibits gamma-aminobutyric acid (GABA) neurons. This action of intrathecal baclofen may be beneficial in the treatment of spasticity and the reduction of muscle spasms caused by cerebral ischemia or cerebral ischemia-like events. The mechanism of action of intrathecal baclofen has been demonstrated in various experimental models and clinical data.
Intrathecal baclofen therapy is indicated for the treatment of spasticity and the reduction of muscle spasms caused by cerebral ischemia or cerebral ischemia-like events.
Intrathecal baclofen should be administered in a dose of 1 mg/kg, in a volume of 1 mL, with a starting dose of 2 mg/kg of baclofen. In patients with intrathecal baclofen therapy, the therapeutic range of dose and duration of treatment is 2 to 10 mg/kg. The therapeutic range of the dose is 10 to 60 mg/kg. The dose of baclofen is usually administered in an interval of 2 to 4 hours.
The dosage of intrathecal baclofen can vary from one institution to another. The maximum recommended dose of intrathecal baclofen is 20 mg/kg, and the daily dose is usually divided into two or three doses. The dose of intrathecal baclofen may be adjusted according to the response and the severity of the condition.
The absorption of baclofen in the oral route of administration has been demonstrated in several studies. In a single oral dose, the mean total plasma concentrations of baclofen were 1.12 ng/mL (95% CI: 1.03-1.25) in patients receiving intrathecal baclofen therapy and 1.09 ng/mL (95% CI: 0.93-1.19) in the placebo group.
The most commonly observed and confirmed effects of baclofen in the clinical trials with intrathecal baclofen therapy were dry mouth and increased appetite. It was found that the dose of baclofen was necessary to improve the symptoms of spasticity and the reduction of muscle spasms after intrathecal baclofen therapy. These findings suggest that the use of intrathecal baclofen therapy is safe and effective in patients with spasticity and the reduction of muscle spasms.
Intrathecal baclofen therapy has the potential to improve the management of spasticity and the reduction of muscle spasms caused by cerebral ischemia or cerebral ischemia-like events. The use of intrathecal baclofen therapy is a safe and effective treatment option in patients with spasticity and the reduction of muscle spasms caused by cerebral ischemia or cerebral ischemia-like events. The benefits of intrathecal baclofen therapy in the treatment of spasticity and the reduction of muscle spasms may be seen in the first few weeks of therapy.
Serious side effects have been reported in patients with intrathecal baclofen therapy.